Fort Lauderdale R&D Tax Credit Benefits for Businesses

R&D Tax Credits for Fort Lauderdale, Florida Businesses

Fort Lauderdale, Florida, thrives in industries such as tourism, healthcare, finance, and logistics. Top companies in the city include Broward Health, a major healthcare provider; AutoNation, a leading automotive retailer; Spirit Airlines, a prominent airline company; JM Family Enterprises, a key financial services provider; and Port Everglades, a major logistics hub. The R&D Tax Credit can benefit these industries by reducing tax liabilities, fostering innovation, and improving business performance. By leveraging the R&D Tax Credit, companies can reinvest savings into advanced research boosting Fort Lauderdale’s economic growth.

Find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 13727 SW 152 Street, Miami is less than 30 miles from Fort Lauderdale and provides R&D tax credit consulting and advisory services to Fort Lauderdale and the surrounding areas such as: Pembroke Pines, Hollywood, Miramar, Coral Springs and Pompano Beach.

If you have any questions or need further assistance, please call or email our local Miami Partner on (786) 404-1316.
Feel free to book a quick teleconference with one of our Florida R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Fort Lauderdale, Florida Patent of the Year – 2024/2025

Advantage Therapeutics Inc. has been awarded the 2024/2025 Patent of the Year for its novel approach to Alzheimer’s disease treatment. Their invention, detailed in U.S. Patent No. 11857568, titled ‘Treatment and prevention of Alzheimer’s disease (AD)’, utilizes an aluminum salt to target and prevent dementias associated with β-amyloid deposition, a hallmark of Alzheimer’s.

This patent underpins ADvantage’s lead candidate, AD04™, a subcutaneous injectable therapy currently in Phase 2b clinical trials across Europe. Unlike traditional treatments focusing solely on amyloid plaques, AD04™ modulates lipid metabolism in the hippocampus, aiming to restore protein expression levels akin to those in younger individuals. This multifaceted mechanism offers both immediate symptomatic relief and long-term disease modification.
AD04™ has demonstrated a favorable safety profile, notably avoiding adverse events like ARIA-E/H, common in other Alzheimer’s treatments. Its immunomodulatory properties stimulate and regulate the immune system, potentially reducing Alzheimer’s pathology without the side effects associated with other therapies.

The ongoing clinical trials aim to confirm AD04™’s efficacy and safety in patients with mild Alzheimer’s disease. If successful, this therapy could represent a significant advancement in Alzheimer’s treatment, offering hope to millions affected by this debilitating condition.